Cochrane · systematic review · CD008740
Tenofovir or zidovudine in three‐drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non‐nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral‐naïve individuals
Spaulding, A, Rutherford, GW, Siegfried, N · Cochrane Database of Systematic Reviews · 2010 · Cochrane Library
HIV/AIDSAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 20%Low 0 · 0%Moderate 2 · 40%High 2 · 40%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
TDF compared to AZT for initial ART
Population: patients with initial ART
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Serious adverse events TDF vs AZT | RR 0.92 [0.6, 1.43] | 2 studies · 586 participants | High |
Virologic response TDF vs AZT | RR 2.04 [0.17, 24.84] | 2 studies · 586 participants | High |
Adherence/tolerability/retention TDF vs AZT | RR 1.17 [1.06, 1.29] | 2 studies · 586 participants | Moderate |
Immunological response TDF vs AZT | no estimate extracted | 1 study · 515 participants | Moderate |
Drug resistance TDF vs AZT | RR 20.43 [1.24, 335.9] | 1 study · 71 participants | Very low |